Total synthesis as a resource in the discovery of potentially valuable antitumor agents: Cycloproparadicicol

Angewandte Chemie - International Edition

Volumn 42, Issue 11, 2003, Pages 1280-1284

  Yamamoto, Kana ^a   Garbaccio, Robert M ^a,c   Stachel, Shawn J ^a   Solit, David B ^a   Chiosis, Gabriela ^a   Rosen, Neal ^a   Danishefsky, Samuel J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antitumor agents; Chaperone proteins; Natural products; Structure activity relationships; Synthesis design

Indexed keywords

DRUG THERAPY; STEREOCHEMISTRY; SYNTHESIS (CHEMICAL); TUMORS;

ANTITUMOR AGENTS;

ORGANIC COMPOUNDS;

ANTINEOPLASTIC AGENT; CYCLOPROPARADICICOL; HEAT SHOCK PROTEIN 90; RADICICOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN MCF 7; CHEMICAL REACTION; CONTROLLED STUDY; CYCLOPROPANATION; CYTOTOXICITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CYCLOPROPANES; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; MACROLIDES; MOLECULAR STRUCTURE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037451452     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200390329     Document Type: Article

References (39)

1. For general reviews of Hsp90, see: a) S. Walter, J. Buchner, Angew. Chem. 2002, 114, 1142-1158; Angew. Chem. Int. Ed. 2002, 41, 1098-1113; b) L. H. Pearl, C. Prodromou, Curr. Opin. Struct. Biol. 2000, 10, 1, 46-51; c) Buchner, Trends Biochem. Sci. 1999, 24, 136-141.
2. For general reviews of Hsp90, see: a) S. Walter, J. Buchner, Angew. Chem. 2002, 114, 1142-1158; Angew. Chem. Int. Ed. 2002, 41, 1098-1113; b) L. H. Pearl, C. Prodromou, Curr. Opin. Struct. Biol. 2000, 10, 1, 46-51; c) Buchner, Trends Biochem. Sci. 1999, 24, 136-141.
3. For general reviews of Hsp90, see: a) S. Walter, J. Buchner, Angew. Chem. 2002, 114, 1142-1158; Angew. Chem. Int. Ed. 2002, 41, 1098-1113; b) L. H. Pearl, C. Prodromou, Curr. Opin. Struct. Biol. 2000, 10, 1, 46-51; c) Buchner, Trends Biochem. Sci. 1999, 24, 136-141.
4. For general reviews of Hsp90, see: a) S. Walter, J. Buchner, Angew. Chem. 2002, 114, 1142-1158; Angew. Chem. Int. Ed. 2002, 41, 1098-1113; b) L. H. Pearl, C. Prodromou, Curr. Opin. Struct. Biol. 2000, 10, 1, 46-51; c) Buchner, Trends Biochem. Sci. 1999, 24, 136-141.
5. For our efforts involving geldanamycin, another natural product which also binds to Hsp90, see: a) S. D. Kuduk, F. F. Zheng, L. Sepp-Lorenzino, N. Rosen, S. J. Danishefsky, Bioorg. Med. Chem. Lett. 1999, 1233-1238; b) S. D. Kuduk, C. R. Harris, F. F. Zheng, L. Sepp-Lorenzino, Q. Ouerfelli, N. Rosen, S. J. Danishefsky, Bioorg. Med. Chem. Lett. 2000, 10, 1303-1306.
6. For our efforts involving geldanamycin, another natural product which also binds to Hsp90, see: a) S. D. Kuduk, F. F. Zheng, L. Sepp-Lorenzino, N. Rosen, S. J. Danishefsky, Bioorg. Med. Chem. Lett. 1999, 1233-1238; b) S. D. Kuduk, C. R. Harris, F. F. Zheng, L. Sepp-Lorenzino, Q. Ouerfelli, N. Rosen, S. J. Danishefsky, Bioorg. Med. Chem. Lett. 2000, 10, 1303-1306.
7. a) L. Neckers, Trends Mol. Med. 2002, 8, 4, S55-S61;
8. b) M. V. Blagosklonny, Leukemia 2002, 16(4), 455-462;
9. c) T. Scheibel, J. Buchner, Biochem. Pharmacol. 1998, 56, 675-682; D.J. Newman, G. M. Cragg, S. Holbeck, E. A. Sausville, Curr. Cancer Drug Targets 2002, 2, 279-308.
10. c) T. Scheibel, J. Buchner, Biochem. Pharmacol. 1998, 56, 675-682; D.J. Newman, G. M. Cragg, S. Holbeck, E. A. Sausville, Curr. Cancer Drug Targets 2002, 2, 279-308.
11. A novel class of synthetic nucleotide analogues was shown to bind to Hsp90 and inhibit the proliferation of cancer cells; see: a) G. Chiosis, M. N. Timaul, B. Lucas, P. N. Munster, F. F. Zheng, L. Sepp-Lorenzino, N. Rosen, Chem. Biol. 2001, 8, 289-299; b) G. Chiosis, B. Lucas, A. Shtil, H. Huezo, N. Rosen, Bioorg. Med. Chem. Lett. 2002, 10, 3555-3564.
12. A novel class of synthetic nucleotide analogues was shown to bind to Hsp90 and inhibit the proliferation of cancer cells; see: a) G. Chiosis, M. N. Timaul, B. Lucas, P. N. Munster, F. F. Zheng, L. Sepp-Lorenzino, N. Rosen, Chem. Biol. 2001, 8, 289-299; b) G. Chiosis, B. Lucas, A. Shtil, H. Huezo, N. Rosen, Bioorg. Med. Chem. Lett. 2002, 10, 3555-3564.
13. P. Delmontte, J. Delmontte-Plaquée, Nature 1953, 171, 344-347.
14. a) S. V. Sharma, T. Agatsuma, H. Nakano, Oncogene 1998, 16, 20, 2639-2645;
15. b) T. W. Schulte, S. Akinaga, T. Murakata, T. Agarsuma, S. Sugimoto, H. Nakano, Y. S. Lee, B. B. Simen, Y. Argon, S. Felts, D. O. Toft, L. M. Neckers, S. V. Sharma, Mol. Endocrinol. 1999, 13(9), 1435-1448.
16. Some derivatives of microbial radicicol were reported to exhibit efficacy in animal models: a) Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, S. Akinaga, Neoplasia 2000, 96, 6, 2284-2291; b) S. Soga, S. V. Sharma, Y. Shiotsu, M. Shimizu, H. Tahara, K. Yamaguchi, Y. Ikuina, C. Murakata, T. Tamaoki, J. Kurebayashi, T. W. Schulte, L. M. Neckers, S. Akinaga, Cancer Chemother. Pharmacol. 2001, 48, 435-445; c) S. Soga, L. M. Neckers, T. W. Schulte, Y. Shiotsu, K. Akasaka, H. Narumi, T. Agatsuma, Y. Ikuina, C. Murakata, T. Tamaoki, S. Akinaga, Cancer Res. 1999, 59, 2931-2938; d) T. Agatsuma, H. Ogawa, K. Akasaka, A. Asai, Y. Yamashita, T. Mizukami, S. Akinaga, Y. Saitoh, Bioorg. Med. Chem. 2002, 10, 3445-3454.
17. Some derivatives of microbial radicicol were reported to exhibit efficacy in animal models: a) Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, S. Akinaga, Neoplasia 2000, 96, 6, 2284-2291; b) S. Soga, S. V. Sharma, Y. Shiotsu, M. Shimizu, H. Tahara, K. Yamaguchi, Y. Ikuina, C. Murakata, T. Tamaoki, J. Kurebayashi, T. W. Schulte, L. M. Neckers, S. Akinaga, Cancer Chemother. Pharmacol. 2001, 48, 435-445; c) S. Soga, L. M. Neckers, T. W. Schulte, Y. Shiotsu, K. Akasaka, H. Narumi, T. Agatsuma, Y. Ikuina, C. Murakata, T. Tamaoki, S. Akinaga, Cancer Res. 1999, 59, 2931-2938; d) T. Agatsuma, H. Ogawa, K. Akasaka, A. Asai, Y. Yamashita, T. Mizukami, S. Akinaga, Y. Saitoh, Bioorg. Med. Chem. 2002, 10, 3445-3454.
18. Some derivatives of microbial radicicol were reported to exhibit efficacy in animal models: a) Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, S. Akinaga, Neoplasia 2000, 96, 6, 2284-2291; b) S. Soga, S. V. Sharma, Y. Shiotsu, M. Shimizu, H. Tahara, K. Yamaguchi, Y. Ikuina, C. Murakata, T. Tamaoki, J. Kurebayashi, T. W. Schulte, L. M. Neckers, S. Akinaga, Cancer Chemother. Pharmacol. 2001, 48, 435-445; c) S. Soga, L. M. Neckers, T. W. Schulte, Y. Shiotsu, K. Akasaka, H. Narumi, T. Agatsuma, Y. Ikuina, C. Murakata, T. Tamaoki, S. Akinaga, Cancer Res. 1999, 59, 2931-2938; d) T. Agatsuma, H. Ogawa, K. Akasaka, A. Asai, Y. Yamashita, T. Mizukami, S. Akinaga, Y. Saitoh, Bioorg. Med. Chem. 2002, 10, 3445-3454.
19. Some derivatives of microbial radicicol were reported to exhibit efficacy in animal models: a) Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, S. Akinaga, Neoplasia 2000, 96, 6, 2284-2291; b) S. Soga, S. V. Sharma, Y. Shiotsu, M. Shimizu, H. Tahara, K. Yamaguchi, Y. Ikuina, C. Murakata, T. Tamaoki, J. Kurebayashi, T. W. Schulte, L. M. Neckers, S. Akinaga, Cancer Chemother. Pharmacol. 2001, 48, 435-445; c) S. Soga, L. M. Neckers, T. W. Schulte, Y. Shiotsu, K. Akasaka, H. Narumi, T. Agatsuma, Y. Ikuina, C. Murakata, T. Tamaoki, S. Akinaga, Cancer Res. 1999, 59, 2931-2938; d) T. Agatsuma, H. Ogawa, K. Akasaka, A. Asai, Y. Yamashita, T. Mizukami, S. Akinaga, Y. Saitoh, Bioorg. Med. Chem. 2002, 10, 3445-3454.
20. a) R. M. Garbaccio, S. J. Danishefsky, Org. Lett. 2000, 2, 20, 3127-3129;
21. b) R. M. Garbaccio, S. J. Stachel, D. K. Baeschlin, S. J. Danishefsky, J. Am. Chem. Soc. 2001, 123, 10903-10908.
22. [10]
23. a) T. C. Chou, X. G. Zhang, C. R. Harris, S. D. Kuduk, A. Balog, K. Savin, J. R. Bertino, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 1998, 95, 15798-15802;
24. b) T. C. Chou, X. G. Zhang, A. Balog, D. Su, D. F. Meng, K. Savin, J. R. Bertino, S. J. Danishefsky, Proc. Natl. Acad. Sci. USA 1998, 95, 9642-9647.
25. S. M. Roe, C. Prodromou, R. O'Brien, J. E. Ladbury, P. W. Piper, L. H. Pearl, J. Med. Chem. 1999, 42, 260-266.
26. a) M. S. Stanford, J. A. Love, R. H. Grubbs, J. Am. Chem. Soc. 2001, 123, 6543-6554, and references therein;
27. b) for reviews, see: A. Fürstner, L. Ackermann, B. Gabor, R. Goddard, C. W. Lehmann, R. Mynott, F. Stelzer, O. R. Thiel, Chem. Eur. J. 2001, 7, 3236-3253;
28. c) A. Fürstner, Angew. Chem. 2000, 112, 3140-3172; Angew. Chem. Int. Ed. 2000, 39, 3012-3043;
29. c) A. Fürstner, Angew. Chem. 2000, 112, 3140-3172; Angew. Chem. Int. Ed. 2000, 39, 3012-3043;
30. d) for an important early example of the use of olefin metathesis for macrocyclization in a functionally complex setting, see: Z. Xu, C. W. Johannes, S. S. Salman, A. H. Hoveyda, J. Am. Chem. Soc. 1996, 118, 10926-10927.
31. K. Yamamoto, K. Biswas, C. Gaul, S. J. Danishefsky, unpublished results.
32. a) A. B. Charette, S. Prescott, C. Brochu, J. Org. Chem. 1995, 60, 1081-1083;
33. b) A. B. Charette, H. Juteau, J. Am. Chem. Soc. 1994, 116, 2651-2652;
34. c) A. B. Charette, H. Juteau, H. Lebel, C. Molinaro, J. Am. Chem. Soc. 1998, 120, 11943-11952;
35. d) A. B. Charette, H. Lebel, Org. Synth. 1999, 76, 86-100.
36. The configuration of the cyclopropane was initially assigned based on Charette's empirical rule and later confirmed by X-ray analysis of the derivative of 14 (see Supporting Information).
37. This trend is consistent with molecular modeling (MOE 2001.01) results (Chiosis, unpublished data).
38. Importantly, the small-cell lung cancer, which is not effected by geldanamycin variant are found to be Rb-negative.
39. On the other hand, other hydrogen bonds in X-ray data appear to be critical as the dimethyl ethers of I and its derivatives lost their activities (data not shown).